Is doxycycline effective for treating ESBL-E cystitis. What are the current recommendations for managing antimicrobial resistant urinary tract infections. How does doxycycline compare to other antibiotics for UTIs caused by resistant bacteria.

Understanding ESBL-E Cystitis and Treatment Challenges

Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) cystitis poses significant treatment challenges due to antibiotic resistance. These infections are becoming increasingly common and difficult to manage with traditional first-line antibiotics.

ESBL enzymes confer resistance to many beta-lactam antibiotics, including penicillins and cephalosporins. This leaves clinicians with limited oral treatment options, especially for outpatient management of uncomplicated cystitis.

Key Characteristics of ESBL-E Cystitis:

• Caused by Enterobacteriaceae (e.g. E. coli, Klebsiella) producing ESBL enzymes
• Resistant to many commonly used antibiotics
• Associated with increased treatment failure rates
• Often requires broader-spectrum or reserve antibiotics
• Can lead to complications if not properly managed

Current Treatment Guidelines and Recommendations

Recent guidelines on managing antimicrobial-resistant gram-negative infections have provided updated recommendations for ESBL-E cystitis. However, there appears to be some debate regarding the role of certain antibiotics like doxycycline.

Are carbapenems always necessary for ESBL-E cystitis. While carbapenems are often recommended for more severe ESBL-E infections, some experts argue they may not always be required for uncomplicated cystitis, especially given concerns about promoting further resistance.

Key Points from Current Guidelines:

• Nitrofurantoin and fosfomycin are preferred oral options if susceptible
• Fluoroquinolones may be used if susceptible, but resistance is increasing
• Trimethoprim-sulfamethoxazole can be considered if susceptible
• Carbapenems are recommended for pyelonephritis or complicated infections
• Aminoglycosides may be an option for some patients

The Potential Role of Doxycycline in ESBL-E Cystitis

Doxycycline has emerged as a potential treatment option for ESBL-E cystitis, particularly in cases where other oral antibiotics are not suitable. However, its efficacy and place in therapy remain subjects of debate among infectious disease specialists.

Why is doxycycline being considered for ESBL-E cystitis. Doxycycline offers several potential advantages, including good oral bioavailability, high urinary concentrations, and activity against many ESBL-producing organisms. Additionally, it may help preserve broader-spectrum antibiotics for more severe infections.

Potential Advantages of Doxycycline:

• Oral formulation allows outpatient treatment
• Achieves high urinary concentrations
• Active against many ESBL-producing bacteria
• Well-tolerated with a favorable side effect profile
• May help reduce use of broader-spectrum antibiotics

Evaluating the Evidence for Doxycycline in ESBL-E Cystitis

The efficacy of doxycycline for ESBL-E cystitis has been supported by several clinical studies, although more robust evidence is needed. A retrospective study by Ren et al. demonstrated clinical success rates comparable to other oral antibiotics for uncomplicated ESBL-E cystitis.

Can doxycycline achieve adequate urinary concentrations to treat ESBL-E cystitis. Pharmacokinetic studies have shown that doxycycline can achieve urinary concentrations well above the minimum inhibitory concentrations (MICs) for many ESBL-producing organisms, suggesting potential efficacy.

Key Findings from Clinical Studies:

• Clinical cure rates of 75-80% for uncomplicated ESBL-E cystitis
• Similar efficacy to other oral options like nitrofurantoin
• Lower recurrence rates compared to some alternatives
• Effective for some fluoroquinolone-resistant strains
• May be particularly useful in patients with limited options

Comparing Doxycycline to Other Antibiotic Options

When considering doxycycline for ESBL-E cystitis, it’s important to evaluate how it compares to other available antibiotic options. Each treatment has its own advantages and limitations that must be carefully weighed.

How does doxycycline compare to nitrofurantoin for ESBL-E cystitis. While both antibiotics can be effective, nitrofurantoin is generally preferred due to more extensive clinical experience and lower potential for collateral damage. However, doxycycline may be a good alternative when nitrofurantoin cannot be used.

Comparison of Antibiotic Options:

Potential Concerns and Limitations of Doxycycline Use

While doxycycline shows promise for treating ESBL-E cystitis, there are several potential concerns and limitations that need to be considered. Understanding these issues is crucial for appropriate patient selection and management.

Does the use of doxycycline for ESBL-E cystitis increase the risk of antimicrobial resistance. There are concerns that widespread use of doxycycline for this indication could lead to increased tetracycline resistance among uropathogens. Careful stewardship and monitoring are essential.

Key Concerns with Doxycycline Use:

• Limited clinical data compared to established options
• Potential for inducing or selecting for tetracycline resistance
• May not be suitable for pregnant women or young children
• Risk of photosensitivity and gastrointestinal side effects
• Possible drug interactions with common medications

Future Research Directions and Clinical Implications

The potential role of doxycycline in treating ESBL-E cystitis highlights the need for further research and clinical studies. As antimicrobial resistance continues to pose challenges, exploring alternative treatment options becomes increasingly important.

What types of studies are needed to better establish the role of doxycycline in ESBL-E cystitis. Randomized controlled trials comparing doxycycline to standard treatment options are crucial. Additionally, pharmacokinetic/pharmacodynamic studies and long-term safety monitoring will provide valuable insights.

Key Areas for Future Research:

1. Large-scale clinical trials comparing doxycycline to established treatments
2. Studies evaluating optimal dosing strategies for urinary tract infections
3. Investigation of combination therapies with doxycycline
4. Long-term monitoring of resistance patterns with doxycycline use
5. Exploration of other tetracycline derivatives for ESBL-E infections

In conclusion, while doxycycline shows potential as a treatment option for ESBL-E cystitis, more robust clinical evidence is needed to fully establish its role. Clinicians should carefully consider the available data, patient factors, and local resistance patterns when making treatment decisions. As research continues, doxycycline may emerge as a valuable addition to the antibiotic armamentarium for managing resistant urinary tract infections.

The ongoing debate surrounding doxycycline use for ESBL-E cystitis underscores the complexities of managing antimicrobial-resistant infections. It highlights the need for continued research, updated guidelines, and individualized treatment approaches. As our understanding evolves, clinicians must stay informed about the latest evidence and recommendations to provide optimal care for patients with resistant urinary tract infections.

Ultimately, the goal is to develop effective treatment strategies that maximize clinical outcomes while minimizing the risk of further antimicrobial resistance. This requires a multifaceted approach involving antimicrobial stewardship, ongoing surveillance, and the exploration of novel treatment options. By carefully evaluating the potential role of antibiotics like doxycycline, we can work towards improving the management of ESBL-E cystitis and other challenging infections.

Doxycycline for ESBL-E Cystitis | Clinical Infectious Diseases

Navbar Search Filter

Clinical Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Mobile Enter search term

Close

Navbar Search Filter

Clinical Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Enter search term

Advanced Search

Journal Article

Tomasz Jodlowski,

Tomasz Jodlowski

Search for other works by this author on:

Oxford Academic

PubMed

Google Scholar

Charles R Ashby, Jr,

Charles R Ashby, Jr

Search for other works by this author on:

Oxford Academic

PubMed

Google Scholar

Sarath G Nath

Sarath G Nath

Search for other works by this author on:

Oxford Academic

PubMed

Google Scholar

Clinical Infectious Diseases, Volume 73, Issue 1, 1 July 2021, Pages e274–e275, https://doi. org/10.1093/cid/ciaa1898

Published:

29 December 2020

Article history

Published:

29 December 2020

Corrected and typeset:

16 February 2021

Navbar Search Filter

Clinical Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Mobile Enter search term

Close

Navbar Search Filter

Clinical Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Enter search term

Advanced Search

To the Editor—With great anticipation we read the recently published ahead-of-print guidance on the treatment of antimicrobial resistant gram-negative infections by Tamma et al [1]. It is a very timely, well written, and useful document. However, we noticed the supporting reference for the statement: “Doxycycline is not recommended for the treatment of extended spectrum beta-lactamase—Enterobacterales (ESBL-E) cystitis due to limited urinary excretion,” on page 6. We do not support this statement as approximately 35%–60% of an oral dose of 100 mg of doxycycline dose is excreted unchanged into the urine [2]. The concentrations of doxycycline following a 100 mg oral dose in the urine can range from 60–300 μg/mL in patients with normal renal function, which is significantly greater than the MIC for the extended spectrum beta-lactamase (ESBL)-E that cause acute cystitis [3, 4].

Clinical data indicate that doxycycline has efficacy against susceptible Gram-positive uropathogens, such as Enterococcus faecalis and E. faecium including vancomycin-resistant E. fecium (VRE) and Gram-negative organisms, including E. coli and K. pneumoniae, that cause urinary cystitis [4–7] Additionally, it was also successful in eradication of VRE in the urine [8].

However, doxycycline is typically not used to treat urinary tract infections. This could be due to the fact that neither doxycycline nor tetracycline are always tested or reported against Gram-negative bacteria. There could also be a lack of knowledge regarding the concentrations reached in the urine that greatly exceed the MIC values for certain uropathogens. Its antimicrobial efficacy is increased in acidic environments, including urine [4]. Given the increased incidence in multidrug-resistant Gram-negative bacterial infections and the favorable pharmacokinetic and safety profile of doxycycline, perhaps its use for treating certain types of acute cystitis should be reconsidered. Following oral administration, 95% of a 100 mg dose of doxycycline is absorbed; doxycycline can be used in patients with renal insufficiency as there is a compensatory increase in nonrenal elimination [9]. Doxycycline is generally well tolerated and the most commonly reported adverse effects include nausea, vomiting, diarrhea, epigastric pain, photosensitivity reactions but the rate of treatment discontinuation is low. It has a low propensity for producing Clostridioides difficile infections [10], meanwhile a normal treatment course is relatively inexpensive. Doxycycline should not be given to pregnant females and children under the age of 8 due to the risk of permanent discoloration of developing teeth [5, 9]. Finally, doxycycline does not inhibit or induce any of the Phase I or II drug metabolizing enzymes, thus decreasing the likelihood of drug–drug interactions,

In conclusion, based on the published pharmacokinetic data and MIC values for uropathogenic ESBL-E, doxycycline reaches levels in the urine that should make it a potential option for the treatment of acute cystitis caused by ESBL-E.

Nonstandard Abbreviations

Nonstandard Abbreviations

 

• ESBL-E

  extended spectrum beta-lactamase Enterobacterales

 

• VRE

  vancomycin-resistant E. fecium

Note

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1.

Tamma

PD

,

Aitken

SL

,

Bonomo

RA

, et al. 

Infectious diseases society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections

.

Clin Infect Dis

2020

:ciaa1478. doi:10.1093/cid/ciaa1478.

2.

Agwuh

KN

,

MacGowan

A

.

Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines

.

J Antimicrob Chemother

2006

;

58

:

256

–

65

.

3.

Cunha

BA

.

Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogens

.

Eur J Clin Microbiol Infect Dis

2012

;

31

:

2865

–

8

.

4.

Cunha

BA

.

An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH

.

Eur J Clin Microbiol Infect Dis

2016

;

35

:

521

–

6

.

5.

White

CR

,

Jodlowski

TZ

,

Atkins

DT

,

Holland

NG

.

Successful doxycycline therapy in a patient with Escherichia coli and multidrug-resistant Klebsiella pneumoniae urinary tract infection

.

J Pharm Pract

2017

;

30

:

464

–

7

.

6.

Lockey

JE

,

Williams

DN

,

Raij

L

,

Sabath

LD

.

Comparison of 4 and 10 days of doxycycline treatment for urinary tract infection

.

J Urol

1980

;

124

:

643

–

5

.

7.

Holloway

WJ

,

Furlong

JH

,

Scott

EG

.

Doxycycline in the treatment of infections of the urinary tract

.

J Urol

1969

;

102

:

249

–

52

.

8.

Kim

Y

,

Bae

S

,

Hwang

S

, et al. 

Does oral doxycycline treatment affect eradication of urine vancomycin-resistant Enterococcus? A tertiary hospital study

.

Yeungnam Univ J Med

2020

;

37

:

112

–

21

.

9.

Joshi

N

,

Miller

DQ

.

Doxycycline revisited

.

Arch Intern Med

1997

;

157

:

1421

–

8

.

10.

Turner

RB

,

Smith

CB

,

Martello

JL

,

Slain

D

.

Role of doxycycline in Clostridium difficile infection acquisition

.

Ann Pharmacother

2014

;

48

:

772

–

6

.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Issue Section:

Correspondence

Download all slides

Advertisement

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Successful Doxycycline Therapy in a Patient With Escherichia coli and Multidrug-Resistant Klebsiella pneumoniae Urinary Tract Infection

Case Reports

. 2017 Aug;30(4):464-467.

doi: 10.1177/0897190016642362.

Epub 2016 Apr 12.

Cassandra R White 
^1
 
2
, Tomasz Z Jodlowski 
²
, Dylan T Atkins 
¹
, Nicole G Holland 
¹

Affiliations

Affiliations

• ¹ 1 Husson University School of Pharmacy, Bangor, ME, USA.
• ² 2 VA Maine Healthcare System, Augusta, ME, USA.

• PMID:

  27071978

• DOI:

  10. 1177/0897190016642362

Case Reports

Cassandra R White et al.

J Pharm Pract.

2017 Aug.

. 2017 Aug;30(4):464-467.

doi: 10.1177/0897190016642362.

Epub 2016 Apr 12.

Authors

Cassandra R White 
^1
 
2
, Tomasz Z Jodlowski 
²
, Dylan T Atkins 
¹
, Nicole G Holland 
¹

Affiliations

• ¹ 1 Husson University School of Pharmacy, Bangor, ME, USA.
• ² 2 VA Maine Healthcare System, Augusta, ME, USA.

• PMID:

  27071978

• DOI:

  10.1177/0897190016642362

Abstract

Objective:

To report on a patient with a symptomatic, polymicrobial Escherichia coli and multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)-positive Klebsiella pneumoniae urinary tract infection (UTI) who was successfully treated with oral doxycycline hyclate.

Case summary:

A 70-year-old white male inpatient with a history of recurrent UTI, type 2 diabetes, hypertension, obesity, and diverticular disease was diagnosed with UTI and empirically treated with oral ciprofloxacin. Symptoms persisted 2 days later, and the patient was transitioned to amoxicillin/clavulanate by a different provider. The next day, upon receipt of the urine culture and susceptibility panel revealing E coli and MDR, ESBL-positive K pneumoniae infection, treatment was switched to doxycycline hyclate, which resulted in clinical improvement.

Discussion:

Complicated UTI involving multiple pathogens requires careful clinical judgment to select the appropriate antimicrobial agent, improve clinical outcomes, and prevent resistance. Treatment with doxycycline was based on the susceptibility panel and local resistance patterns. Advantages of doxycycline for UTI include its oral formulation, wide spectrum of activity, ability to achieve high concentration in the urine, and low toxicity.

Conclusion:

Doxycycline hyclate may be an effective treatment option for patients with susceptible MDR UTI.

Keywords:

bacterial resistance; doxycycline; infectious disease; urology.

Similar articles

• Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.

  Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K.

  Cho YH, et al.
  Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31.
  Int Urol Nephrol. 2015.

  PMID: 26026972

• Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

  Titelman E, Iversen A, Kalin M, Giske CG.

  Titelman E, et al.
  Microb Drug Resist. 2012 Apr;18(2):189-92. doi: 10. 1089/mdr.2011.0161. Epub 2011 Dec 28.
  Microb Drug Resist. 2012.

  PMID: 22204597

  Clinical Trial.

• CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia.

  Martinez P, Garzón D, Mattar S.

  Martinez P, et al.
  Braz J Infect Dis. 2012 Sep-Oct;16(5):420-5. doi: 10.1016/j.bjid.2012.05.001. Epub 2012 Sep 8.
  Braz J Infect Dis. 2012.

  PMID: 22964287

• Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.

  Mazzariol A, Bazaj A, Cornaglia G.

  Mazzariol A, et al.
  J Chemother. 2017 Dec;29(sup1):2-9. doi: 10.1080/1120009X.2017.1380395.
  J Chemother. 2017.

  PMID: 29271736

  Review.

• Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern.

  Padmini N, Ajilda AAK, Sivakumar N, Selvakumar G.

  Padmini N, et al.
  J Basic Microbiol. 2017 Jun;57(6):460-470. doi: 10.1002/jobm.201700008. Epub 2017 Apr 11.
  J Basic Microbiol. 2017.

  PMID: 28397262

  Review.

See all similar articles

Cited by

• Comparison of ciprofloxacin, cotrimoxazole, and doxycycline on Klebsiella pneumoniae: Time-kill curve analysis.

  Setiawan A, Widodo ADW, Endraswari PD.

  Setiawan A, et al.
  Ann Med Surg (Lond). 2022 Nov 5;84:104841. doi: 10.1016/j.amsu.2022.104841. eCollection 2022 Dec.
  Ann Med Surg (Lond). 2022.

  PMID: 36536710
  Free PMC article.

• Effectiveness of oral antibiotics for treating pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: A case series.

  Terada N, Itoh N, Kurai H.

  Terada N, et al.
  J Gen Fam Med. 2020 Apr 10;21(4):127-133. doi: 10.1002/jgf2.320. eCollection 2020 Jul.
  J Gen Fam Med. 2020.

  PMID: 32742901
  Free PMC article.

• Use of ceragenins as a potential treatment for urinary tract infections.

  Wnorowska U, Piktel E, Durnaś B, Fiedoruk K, Savage PB, Bucki R.

  Wnorowska U, et al.
  BMC Infect Dis. 2019 May 2;19(1):369. doi: 10.1186/s12879-019-3994-3.
  BMC Infect Dis. 2019.

  PMID: 31046689
  Free PMC article.

• Pathogen Identification Direct From Polymicrobial Specimens Using Membrane Glycolipids.

  Fondrie WE, Liang T, Oyler BL, Leung LM, Ernst RK, Strickland DK, Goodlett DR.

  Fondrie WE, et al.
  Sci Rep. 2018 Oct 26;8(1):15857. doi: 10.1038/s41598-018-33681-8.
  Sci Rep. 2018.

  PMID: 30367087
  Free PMC article.

Publication types

MeSH terms

Substances

Cheap analogs of expensive antibiotics: analogs of expensive drugs

Antibiotics are one of the most expensive groups of drugs. And if the cost of “old” antibiotics is more or less acceptable, then new broad-spectrum antibiotics are incredibly expensive, which is not surprising, because the development of one new antibiotic costs approximately 1 billion US dollars.

If you think about this topic, you can understand that there are not so many new antibiotics, because not only do development and clinical studies take decades, but also the cost of the project is equal to the cost of space flight. In this regard, very few pharmaceutical companies in the US and Europe can conduct such expensive research.

For example, Linezolid (trade name Zyvox) is the latest antibiotic to enter the market and is patented by Pfizer. At the same time, it was synthesized back in 1990, and only in 2000 was it first put into practice.

And what about other pharmaceutical companies, including domestic ones, who cannot afford such expenses? The answer is simple – they produce generics, that is, analogues of already well-known antibiotics, with the same active ingredient as the original drug, but under a different trade name. The cost of such drugs is often lower than the cost of the original drug, but there are also opposite cases.

When prescribing antibiotic therapy, doctors can prescribe both the original drug – an expensive antibiotic (occurs less often), and its analogue – a cheap antibiotic (in most cases). The reason for this is the work of medical representatives of pharmaceutical companies and distributors. So if the doctor prescribed you an expensive antibiotic, do not rush to buy it at the expense of the budget. Most likely, he has a cheaper analogue, which a pharmacist in a pharmacy can also advise you if you ask him about it. However, it is worth remembering that from January 1, 2023 in Ukraine, you can buy an antibiotic only with an electronic prescription, which is pre-written to you by a doctor. The Doc.ua service also provides an opportunity to get an electronic prescription for antibiotics in just a few clicks. You can also buy all the necessary prescription drugs at the Doc.ua Pharmacy.

In this article we have provided a list of analogues of the most famous and widely used antibiotics.

Antibiotics for colds list Ukraine

Antibiotics of the penicillin group

Flemoxin Solutab , cases of bronchitis, sinusitis, pneumonia, peptic ulcer, cystitis and other

The average cost of Flemoxin Solutab and Ospamox is 80-150 UAH. Its analogue is Amoxil (amoxicillin analogues, amoxiclav analogues). The average cost is 50-70 UAH (inexpensive antibiotics for colds).

Antibiotics of the group of inhibitor-protected aminopenicillins

Flemoklav Solutab , Augmentin (amoxicillin and clavulanic acid).

This antibiotic is used to treat mild and uncomplicated cases of bronchitis, sinusitis, pneumonia, peptic ulcers, cystitis, etc. caused by b-lactamase producing bacteria.

The average cost of Flemoclav Solutab is 100-150 UAH, Augmentin is 130-190 UAH.

Flemoklav Solutab analogues, Augmentin analogues ( cheap broad-spectrum antibiotics):

Bactoclav is the cheapest antibiotic, the average price is 60 – 70 UAH.

Amoxil K, Medoklav, Abiklav, Amoksiklav 2x, Betaklav, are also inexpensive antibiotics for colds.

Antibiotics of the cephalosporin group

Emsef , Rotacef , Blitzef , Diacef , Denicef ​​ (ceftriaxone analogues in tablets) – Lorakson, Medakson (ceftriaxone analogue in tablets), Ceftriaxone-Darnitsa, Ceftriaxone-KMP, Ceftriaxone-Lekhim.

Antibiotics treat diseases such as sepsis, meningitis, disseminated Lyme borreliosis (early and late stages of the disease), infections of the abdominal cavity, etc. 27 (cefuroxime) – Aksetin, Aksef , Auroxetil.

Antibiotics treat urinary tract infections – cystitis, pyelonephritis, urethritis; skin and soft tissues – furunculosis, pyoderma, impetigo, etc.

Quadrocef , Roxipim , Abipim , Denipim 900 26, Exipim , Septipim (cefepime) – Cefepim-Lekhim, Cefepim Abryl, Cefepim Aurobindo.

Antibiotics treat respiratory diseases (pneumonia and bronchitis), urinary tract infections, and skin and soft tissue infections.

Eurosidim , Ceftazidime-Vista (ceftazidime) – Ceftazidime Yuria-pharm, Ceftum, Zacef, Ceftazidime-BHFZ.

These antibiotics are used to treat meningitis, sepsis and other illnesses.

Sorcef , Cefinac , Suprax Solutab (cefixime) – Lopraks, Opticef, Cefix.

Antibiotics treat diseases such as pharyngitis, tonsillitis, sinusitis, acute and chronic bronchitis, otitis media, and urinary tract infections.

Macrolide antibiotics

Sumamed , Azax , Azitrox , Aztec , Hemomycin , 9002 6 Zybax (azithromycin analogues are expensive, sumamed analogues) – Azibiot, Azipol, Zitrox, Ormax, Azimed (the best analogue sumamed) Azicin, Zoxy, Azithromycin-Astrapharm, Azithromycin-Health, Azithromycin-BHFZ, Azithromycin-Red Star, Ziomycin (azithromycin analogues of the drug).

These name antibiotics are used to treat pharyngitis, tonsillitis, sinusitis, otitis media, as well as acute bronchitis, pneumonia. 9Ora dro (clarithromycin analogs) – Aziklar, Clarithromycin-Health, Clarithromycin-Astrapharm, Clarithromycin-Darnitsa, Clarithromycin-Arterium, Clubax.

Antibiotics treat diseases such as infections of the upper respiratory tract and ENT organs: tonsillopharyngitis, otitis media, acute sinusitis, as well as infections of the lower respiratory tract: acute bronchitis, exacerbation of chronic bronchitis and others.

Antibiotics of the tetracycline group

Unidox Solutab (doxycycline) – its inexpensive antibiotics – analogues: Doxycycline-Teva, Doxycycline-Darnitsa, Doxycycline-BHFZ (inexpensive antibiotic).

Antibiotics are used to treat pharyngitis, bronchitis, tracheitis, bronchopneumonia, as well as otitis media, tonsillitis, sinusitis and others.

Antibacterial drugs of the fluoroquinolone group

Ofloxin (ofloxacin) – Ofloxacin-Darnitsa, Ofloxacin-Lekhim (inexpensive antibiotic).

Antibiotics treat infectious and inflammatory diseases of bones and joints, abdominal cavity, diseases of the kidneys (pyelonephritis) and urinary tract (cystitis, urethritis.

Abiflox , Levaksela, Lebel , Levoksimed, Levomak , Tigeron (levofloxacin) – Levokilz, Levofloxacin-Lekhim, Levofloxacin-Health, Floxium, Leflok.

Antibiotics are used to treat acute sinusitis, exacerbations of chronic bronchitis, community-acquired pneumonia, complicated urinary tract infections.

Avelox , Moxicum, Timoksi, Moxifloxacin-Sandoz (moxifloxacin) – Moxifloxacin-Lekhim, Moflaxa, Moxifloxacin-Pharmex, Atovax.

Antibiotics are used to treat acute sinusitis, exacerbations of chronic bronchitis, community-acquired pneumonia.

Cifran , Tsiprinol , Tsiprolet analogues , Flaprox, 900 26 Ciprobel (ciprofloxacin analogues are expensive) – Ciprofloxacin-Euro, Ciprofloxacin-Lekhim, Ciprofloxacin-Astrapharm, Citeral.

An antibiotic is used to treat sepsis and peritonitis and to prevent and treat infections in immunosuppressed patients.

Nitroimidazole antibacterials

Strong antibiotics in tablets

Trichopolum , Efloran (metronidazole) – Metrogyl, Metressa, Metronidazole-Health, Metronidazole-Darnitsa, Metronidazole-Infusion, Metronid Zol-Yuria Pharm, Metronidazole Lubnypharm.

Antibiotics treat protozoal infections: extraintestinal amoebiasis, including amoebic liver abscess, intestinal amoebiasis (amebic dysentery), trichomoniasis, giardiasis, balantidiasis, cutaneous leishmaniasis, trichomonas vaginitis, trichomonas urethritis, and others.

Ornigil , Ornizol, Ornimac (ornidazole) – Ornidazol-Darnitsa, Ornidazol-Novofarm, Ornidazol-Infusion.

Antibiotics are used to treat trichomoniasis, amoebiasis, giardiasis, and a mild antibiotic is used to prevent postoperative complications.

Antibiotic analogues table

Help DOC.ua: You can sign up for a consultation with a general practitioner on the website.

Urethritis | Dikul Center

Urethritis is a disease in which there is inflammation and irritation of the urethra, which is the passageway for urine from the bladder. Sperm also passes through the urethra in men.

Urethritis usually presents with pain when urinating and an urge to urinate frequently. The leading cause of urethritis is infection of the urethra by various bacteria.

Urethritis – differs from urinary tract infection in that the inflammation and infection affects only the urethra locally. The symptoms of a UTI may be the same as those of urethritis, but treatment will vary depending on the cause of the urethritis.

Urethritis can develop in people of any age and occurs in both women and men. However, women are at a higher risk of developing urethritis than men because the urethra is much shorter in women, which increases the risk of bacteria entering the urethra.

In 80% of cases, urethritis has a non-gonococcal origin.

Symptoms

Symptoms in men

Men with urethritis may have the following symptoms:

• Burning urination
• itching or burning sensation near the opening of the urethra
• blood in urine or semen
• discharge from the urethra

Symptoms in women

Women with urethritis may have the following symptoms:

• frequent urge to urinate
• urinary discomfort
• burning sensation or irritation in the area of ​​the urethral orifice
• possible abnormal discharge from the vagina.

At the same time, urethritis may be asymptomatic in some people, especially in women. In men, urethritis can also occur without symptoms if caused by infections such as chlamydia or Trichomonas.

For this reason, testing for (STIs) is essential when infections are suspected.

Causes

Most cases of urethritis are caused by infection: viruses or bacteria. The most common cause of urethritis is bacteria that can infect both the lining of the urethra and the bladder or kidneys. Bacteria that naturally live in the genital area can also cause urethritis if they enter the urinary tract.

Bacteria that can cause urethritis include:

• Neisseria gonorrhea
• Chlamydia trachomatis
• Mycoplasma genitalium

Urethritis can also be caused by protozoa such as trichomoniasis.

In addition, some viruses (human papillomavirus, herpes simplex and cytomegalovirus) can also cause urethritis.

Types

There are different types of urethritis classified according to the genesis of the inflammation. These are gonococcal urethritis and non-gonococcal urethritis.

Gonococcal urethritis is caused by the bacterium gonorrhea. Such an infection is the cause of urethritis in 20 percent of cases.

Non-gonococcal urethritis – not caused by gonorrhea, but by other infections. Chlamydia is a common cause of non-gonococcal urethritis, and other STIs can also cause inflammation of the urethra.

However, urethral irritation not associated with STIs may occur. These causes may be trauma to the genitals or, for example, damage to the urethra after using the catheter.

Urethritis can have multiple causes, especially in women.

Diagnosis

After your doctor has your symptoms and history, your doctor will also examine your genital area for discharge, tenderness, sores, and other signs of an STI. This can help the doctor make a diagnosis.

Your doctor may also order a urine or swab test from the urethra or vaginal area. If a specific STI is suspected, other blood tests may be ordered to look for other STIs, such as HIV and syphilis.

Within a few days, the results of the tests will be ready, and the doctor can prescribe treatment. Often, the partner also has to undergo examination and treatment.

Treatment

Urethritis is usually treated with medication, such as antibiotics or antivirals.

The most common drugs for treating urethritis are:

• azithromycin, an antibiotic, usually given as a single dose
• doxycycline
• erythromycin
• ofloxacin
• levofloxacin

If urethritis is caused by an STI, it is essential that all sexual partners be evaluated and treated if necessary. This helps to prevent re-infection and eliminate the risk of spreading STIs.

Symptoms usually improve within a few days of starting treatment. However, it is necessary to complete the fully recommended course of treatment and resume sexual activity no earlier than one week after completion of treatment.

Potential adverse effects may occur with drug interactions used to treat urethritis when taken with:

• blood thinners
• heart drugs
• anticonvulsants

Complications

Medications, if administered in time, allow you to quickly get rid of urethritis. However, if the infection is left untreated, the consequences can be long-term and very serious. The infection can spread to other parts of the urinary tract, including the bladder, ureters, and kidneys. If the urinary tract is affected, treatment is longer, and if left untreated, complications can be long-term and cause organ damage. Infections can also spread through the blood and lead to sepsis, which can be fatal.

In addition, STIs, which often cause urethritis, can cause problems with the reproductive system. Women can develop pelvic inflammatory disease (PID), which can cause infertility, pain during sex, or persistent pelvic pain. Women with untreated STIs also have a higher risk of ectopic pregnancy, which can be fatal.

In men, urethritis can lead to infection of the prostate or narrowing of the urethra due to scarring, resulting in painful urination. For these reasons, if you have any symptoms of urethritis, you should consult a doctor.

Prevention

Many of the bacteria that cause urethritis can be passed on to another person through sexual contact.